Switching from mavacamten to aficamten in obstructive hypertrophic cardiomyopathy
Tests aficamten as a switch from mavacamten in adults with obstructive hypertrophic cardiomyopathy.
Plain-language title generated from the registry record
Registry title: Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Key facts
- Where
- Kansas City and Portland, United StatesSee the 2 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07600177, who can take part
Where in United States
- St. Luke's Hospital - Mid America Heart InstituteKansas City, United StatesNot yet recruiting
- Oregon Health Science UniversityPortland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oregon Health and Science University
- Trial code
- NCT07600177
- Record updated
- 20 May 2026
- Original description
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).Read full original descriptionShow less
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).
Inclusion: Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially; Echo-derived LVEF ≥55% on mavacamten at the time of enrollment; Patient willing to consent for the study and undergo the study procedures.
Exclusion: Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis); Documented history of current obstructive coronary artery disease (> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction; History of LVEF <30%; Severe aortic stenosis or sub-aortic obstruction; Paroxysmal atrial fibrillation (AF) with documented episode within 3 months; Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation.